Literature DB >> 19172223

The role of estrogen receptor-alpha gene TA polymorphism and aromatase gene TTTA polymorphism on peak bone mass attainment in males: is there an additive negative effect of certain allele combinations?

Darko Kastelan1, Zorana Grubic, Ivana Kraljevic, Ozren Polasek, Tina Dusek, Katarina Stingl, Vesna Kerhin-Brkljacic, Mirko Korsic.   

Abstract

Idiopathic osteoporosis in males is influenced predominantly by low peak bone mass as a feature under a strong genetic control. Among a number of candidate genes, alpha-estrogen receptor (ERalpha) and CYP19 genes are of particular interest due to important role of estrogen in pathophysiology of osteoporosis. In the present study we examined the association of certain allelic combinations of ERalpha gene thymine-adenine (TA) polymorphism and aromatase gene TTTA polymorphism on bone mineral density (BMD) in young men. The study sample consisted of 92 unrelated healthy male volunteers, aged 21-35. In each subject, lumbar spine and proximal femur BMD, parameters of bone turnover and 25-OHD level were measured. Two ERalpha (TA)( n ) alleles, allele 19 and allele 21, were found to be associated with lower BMD. The presence of allele 19 was associated with significantly lower lumbar spine (P = 0.006) and trochanter (P = 0.02) BMD while the subjects positive for allele 21 had significantly lower lumbar spine (P = 0.04), trochanter (P = 0.02) and total hip (P = 0.03) BMD. Men with CYP19 (TTTA)(7-3)/ERalpha (TA)(19) allele combination had significantly lower lumbar spine BMD (P = 0.02) and those with CYP19 (TTTA)(7-3)/ERalpha (TA)(21) allele combination had significantly lower BMD for all three measurements, i.e. lumbar spine (P = 0.02), femoral neck (P = 0.02) and total hip (P = 0.008). These particular combinations of high-risk alleles were associated with lower median lumbar spine, femoral neck and total hip BMD than either of the allele alone suggesting that negative effect of two risk alleles on peak bone mass add up.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19172223     DOI: 10.1007/s00774-008-0029-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  27 in total

1.  Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males.

Authors:  B Ongphiphadhanakul; R Rajatanavin; S Chanprasertyothin; N Piaseu; L Chailurkit
Journal:  Clin Endocrinol (Oxf)       Date:  1998-12       Impact factor: 3.478

2.  Association of estrogen receptor-alpha gene polymorphisms with bone mineral density in postmenopausal Korean women.

Authors:  Hae-Sung Nam; Min-Ho Shin; Sun-Seog Kweon; Kyeong-Soo Park; Seok-Jun Sohn; Jung-Ae Rhee; Jin-Su Choi; Myung-Ho Son
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  Reduced androgen receptor gene expression with first exon CAG repeat expansion.

Authors:  C S Choong; J A Kemppainen; Z X Zhou; E M Wilson
Journal:  Mol Endocrinol       Date:  1996-12

4.  Estrogen receptor alpha gene polymorphisms and bone mineral density: haplotype analysis in women from the United Kingdom.

Authors:  O M Albagha; F E McGuigan; D M Reid; S H Ralston
Journal:  J Bone Miner Res       Date:  2001-01       Impact factor: 6.741

5.  Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model.

Authors:  D Vanderschueren; S Boonen; A G Ederveen; R de Coster; E Van Herck; K Moermans; L Vandenput; A Verstuyf; R Bouillon
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

6.  Prediction of bone density from vitamin D receptor alleles.

Authors:  N A Morrison; J C Qi; A Tokita; P J Kelly; L Crofts; T V Nguyen; P N Sambrook; J A Eisman
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

7.  Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.

Authors:  E P Smith; J Boyd; G R Frank; H Takahashi; R M Cohen; B Specker; T C Williams; D B Lubahn; K S Korach
Journal:  N Engl J Med       Date:  1994-10-20       Impact factor: 91.245

8.  Runx2 integrates estrogen activity in osteoblasts.

Authors:  Thomas L McCarthy; Wei-Zhong Chang; Yuan Liu; Michael Centrella
Journal:  J Biol Chem       Date:  2003-09-01       Impact factor: 5.157

9.  Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

Authors:  Matthew R Smith; Mary Anne Fallon; Hang Lee; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

10.  Vitamin D and estrogen receptor-alpha genotype and indices of bone mass and bone turnover in Danish girls.

Authors:  Siobhan Cusack; Christian Mølgaard; Kim F Michaelsen; Jette Jakobsen; Christel J E Lamberg-Allardt; Kevin D Cashman
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.976

View more
  4 in total

1.  Different reference BMDs affect the prevalence of osteoporosis.

Authors:  Ki Jin Jung; Chin Youb Chung; Moon Seok Park; Soon-Sun Kwon; Sang Young Moon; In Hyeok Lee; Ka Hyun Kim; Kyoung Min Lee
Journal:  J Bone Miner Metab       Date:  2015-06-10       Impact factor: 2.626

Review 2.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

3.  An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.

Authors:  Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson
Journal:  Fertil Steril       Date:  2009-12-11       Impact factor: 7.329

4.  The effect of testosterone itself and in combination with letrozole on bone mineral density in male rats.

Authors:  Forough Saki; Seyed Reza Kasaee; Faezeh Sadeghian; Pedram Talezadeh; Gholam Hossein Ranjbar Omrani
Journal:  J Bone Miner Metab       Date:  2018-11-03       Impact factor: 2.626

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.